Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal

Abstract

The results of the ROADSTER trial demonstrate that the use of the ENROUTE Transcarotid NPS is safe and effective at preventing stroke during CAS. The overall stroke rate of 1.4% is the lowest reported to date for any prospective, multicenter clinical trial of CAS.

Lights Out: An Unusual Case of Amaurosis Fugax

“…2 The patient’s visual symptoms disappeared immediately after this procedure, and she was found to be in good health in clinic 1 month and then 5 months after the procedure.…”

“…The patient’s atorvastatin was increased from 10 mg to 40 mg once daily. The patient was referred to a vascular surgeon, who recommended performing brachiocephalic stenting retrogradely as previously reported 2 (Figure 2). The patient tolerated the procedure well, without procedure or postoperative complications.…”

Transcervical access, reversal of flow and mesh-covered stents: New options in the armamentarium of carotid artery stenting

“…Not long ago, the Reverse Flow Used During CAS Procedure (ROADSTER) multicenter trial reported its results from the evaluation of the safety and efficacy of the ENROUTE Transcarotid NPS (Silk Road Medical Inc, Sunnyvale, Calif), a novel transcarotid neuroprotection system that provides direct surgical common carotid access and cerebral embolic protection via high-rate flow reversal during CAS[29]. This study reported an overall stroke rate of 1.4%, which is the lowest reported for any prospective multicenter clinical trial of CAS.…”

“…This study reported an overall stroke rate of 1.4%, which is the lowest reported for any prospective multicenter clinical trial of CAS. The stroke/death rates (2.8%) and the stroke/death/MI rates (3.5%) reported were also similarly low[29]. …”

Commentary: Carotid Artery Revascularization for Stroke Prevention

“…The symptomatic transformation of atherosclerotic CS, however, is far from being eradicated. Consequently, contemporary carotid revascularization studies [11][12][13] continue to include up to 55% symptomatic subjects in all-comer patient series. 11 A significant proportion of these patients are already on antiplatelet and maximized statin treatment prior to the CS-associated stroke events, 11,14,15 consistent with the fact that medical therapy reduces but does not abolish the CS stroke risk.…”